接受托珠单抗治疗的患者发生肠壁积气和肠穿孔
Pneumatosis Intestinalis and Intestinal Perforation in a Patient Receiving Tocilizumab.
作者信息
Jacobs Ben, Jawad Ali, Fattah Zozik
机构信息
Department of Rheumatology, Barts Health NHS Trust, London, United Kingdom.
出版信息
Arch Rheumatol. 2018 Jan 17;33(3):372-375. doi: 10.5606/ArchRheumatol.2018.6668. eCollection 2018 Sep.
Abstract
In this article, we report a case of pneumatosis intestinalis associated with tocilizumab use. This is a unique case and may explain the increased rate of idiopathic bowel perforation among patients taking tocilizumab.
摘要
在本文中，我们报告了一例与使用托珠单抗相关的肠壁囊样积气病例。这是一个独特的病例，可能解释了服用托珠单抗的患者中特发性肠穿孔发生率增加的原因。
相似文献
1
Pneumatosis Intestinalis and Intestinal Perforation in a Patient Receiving Tocilizumab.接受托珠单抗治疗的患者发生肠壁积气和肠穿孔
Arch Rheumatol. 2018 Jan 17;33(3):372-375. doi: 10.5606/ArchRheumatol.2018.6668. eCollection 2018 Sep.
2
Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management.肠气肿和肠穿孔与分子靶向治疗相关：一个新出现的问题和放射科医生在其管理中的作用。
AJR Am J Roentgenol. 2012 Dec;199(6):1259-65. doi: 10.2214/AJR.12.8782.
3
Successful treatment with hyperbaric oxygen therapy for pneumatosis cystoides intestinalis as a complication of granulomatosis with polyangiitis: a case report.高压氧疗法成功治疗肉芽肿性多血管炎并发症肠壁囊样积气症：一例报告
J Med Case Rep. 2017 Sep 17;11(1):263. doi: 10.1186/s13256-017-1421-1.
4
[A Case of Colorectal Cancer with Asymptomatic Idiopathic Pneumatosis Intestinalis during Bevacizumab Administration].[1例在使用贝伐单抗期间出现无症状特发性肠气囊肿的结直肠癌病例]
Gan To Kagaku Ryoho. 2020 Jul;47(7):1109-1111.
5
Pneumatosis Intestinalis After Molecular-Targeted Therapy.肠壁积气症在分子靶向治疗后。
World Neurosurg. 2019 May;125:312-315. doi: 10.1016/j.wneu.2019.01.225. Epub 2019 Feb 11.
6
Conservative management of pneumatosis intestinalis.小肠积气的保守治疗
Gynecol Oncol. 2005 Dec;99(3):782-4. doi: 10.1016/j.ygyno.2005.08.008. Epub 2005 Sep 19.
7
Colonic stenting for malignant colonic obstruction with pneumatosis intestinalis: A case report.结肠支架置入术治疗合并肠壁积气的恶性结肠梗阻：一例报告
Int J Surg Case Rep. 2016;26:38-41. doi: 10.1016/j.ijscr.2016.07.012. Epub 2016 Jul 14.
8
Pneumatosis and pneumoperitoneum in chronic idiopathic intestinal pseudoobstruction.慢性特发性肠道假性梗阻中的气肿和气腹
J Pediatr Surg. 1991 Dec;26(12):1384-6. doi: 10.1016/0022-3468(91)91039-2.
9
When the Benign Pneumatosis Intestinalis Becomes No Longer Benign: A Rare Case of Bowel Perforation in a Patient with Systemic Sclerosis.良性肠积气症恶变时：系统性硬化症患者肠道穿孔的罕见病例
Case Rep Gastrointest Med. 2018 Aug 26;2018:5124145. doi: 10.1155/2018/5124145. eCollection 2018.
10
Laparoscopically assisted subtotal colectomy for idiopathic pneumatosis cystoides intestinalis.腹腔镜辅助下全结肠次全切除术治疗特发性肠壁囊样积气症
Acta Chir Belg. 2006 May-Jun;106(3):346-7. doi: 10.1080/00015458.2006.11679904.
引用本文的文献
1
Case Report: long-term clinical outcomes in -associated acute necrotizing encephalopathy.病例报告：与……相关的急性坏死性脑病的长期临床结局
Front Pharmacol. 2025 Jun 5;16:1607682. doi: 10.3389/fphar.2025.1607682. eCollection 2025.
2
Pneumatosis Intestinalis in the Setting of COVID-19: A Single Center Case Series From New York.2019冠状病毒病背景下的肠壁积气：来自纽约的单中心病例系列
Front Med (Lausanne). 2021 Jun 4;8:638075. doi: 10.3389/fmed.2021.638075. eCollection 2021.
3
Bowel ulceration following tocilizumab administration in a COVID-19 patient.一名COVID-19患者使用托珠单抗后出现肠道溃疡。
BMJ Open Gastroenterol. 2020 Aug;7(1). doi: 10.1136/bmjgast-2020-000484.
本文引用的文献
1
Lesson of the month 1: Septic arthritis with normal acute phase reactants and white cell count in a patient receiving tocilizumab.本月病例 1：接受托珠单抗治疗的患者出现急性期反应物和白细胞计数正常的脓毒性关节炎
Clin Med (Lond). 2017 Jun;17(3):280-281. doi: 10.7861/clinmedicine.17-3-280.
2
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.与使用其他生物制剂或传统合成改善病情抗风湿药治疗相比，使用托珠单抗治疗的类风湿关节炎患者发生下肠道穿孔的风险。
Ann Rheum Dis. 2017 Mar;76(3):504-510. doi: 10.1136/annrheumdis-2016-209773. Epub 2016 Jul 12.
3
IL-6 as a keystone cytokine in health and disease.IL-6 作为健康与疾病中的关键细胞因子。
Nat Immunol. 2015 May;16(5):448-57. doi: 10.1038/ni.3153.
4
The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis.2013年英国风湿病学会（BSR）和英国风湿病卫生专业人员协会（BHPR）关于静脉注射托珠单抗治疗成年类风湿关节炎患者的指南。
Rheumatology (Oxford). 2014 Jul;53(7):1344-6. doi: 10.1093/rheumatology/keu168. Epub 2014 May 12.
5
Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study.托珠单抗治疗肿瘤坏死因子抑制剂治疗抵抗的类风湿关节炎患者的健康相关生活质量改善：来自 24 周随机对照 RADIATE 研究的结果。
Rheumatology (Oxford). 2012 Oct;51(10):1860-9. doi: 10.1093/rheumatology/kes131. Epub 2012 Jun 28.
6
Successful conservative treatment of pneumatosis intestinalis associated with intraperitoneal free air: report of a case.成功保守治疗伴腹腔游离气体的气腹症 1 例报告。
Surg Today. 2012 Oct;42(10):992-6. doi: 10.1007/s00595-012-0184-y. Epub 2012 Jun 16.
7
Tocilizumab for rheumatoid arthritis.托珠单抗用于治疗类风湿关节炎。
Cochrane Database Syst Rev. 2010 Jul 7(7):CD008331. doi: 10.1002/14651858.CD008331.pub2.
8
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.托珠单抗抑制白细胞介素-6受体对类风湿关节炎患者的影响（OPTION研究）：一项双盲、安慰剂对照的随机试验。
Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5.
9
Cytokines in the pathogenesis of rheumatoid arthritis.细胞因子在类风湿关节炎发病机制中的作用
Nat Rev Immunol. 2007 Jun;7(6):429-42. doi: 10.1038/nri2094.
10
Pneumatosis intestinalis in the adult: benign to life-threatening causes.成人肠壁积气：从良性病因到危及生命的病因
AJR Am J Roentgenol. 2007 Jun;188(6):1604-13. doi: 10.2214/AJR.06.1309.
Zotero 插件